Navigation Links
Otonomy Acquires Assets and Patent Rights for Tinnitus Program
Date:10/31/2013

SAN DIEGO, Oct. 31, 2013 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it has completed the acquisition of certain assets and rights to intellectual property (IP) related to the use of gacyclidine for the treatment of tinnitus from an affiliate of NeuroSystec Corporation. Successful serial entrepreneur Alfred Mann founded NeuroSystec to develop a drug-device combination product that could provide sustained delivery of gacyclidine to the inner ear. Gacyclidine is a potent and selective antagonist of the N-Methyl-D-Aspartate (NMDA) receptor. Clinical studies, including pilot studies conducted with gacyclidine, support the use of NMDA antagonists as treatments for tinnitus. The company's third development program, OTO-311, utilizes Otonomy's proprietary drug delivery technology to achieve sustained exposure of gacyclidine in the inner ear from a single intratympanic (IT) injection.

(Logo: http://photos.prnewswire.com/prnh/20130806/MM59802LOGO)

The acquisition provides the company with preclinical, clinical, and manufacturing data produced by NeuroSystec in its development of gacyclidine, which was delivered to the inner ear via a pump and micro-catheter for the treatment of tinnitus. In addition, the company also acquired intellectual property rights including issued and pending patent applications that augment the current patent estate protecting OTO-311.

"Emerging clinical data combined with completion of this transaction help set the stage for a streamlined development path for OTO-311 as a treatment for tinnitus," said David A. Weber, Ph.D., president and CEO of Otonomy. "Furthermore, the addition of this third program to our product pipeline exemplifies our commitment to broadly address unmet medical need in the treatment of otic disorders."

"We are pleased to transfer the data and results from our efforts, and IP surrounding gacyclidine to further the development of OTO-311. We believe that prolonged drug exposure to the inner ear is essential for optimal treatment and that Otonomy's technology featuring single injection delivery is a patient friendly innovation," stated Alfred Mann. "OTO-311 has exciting potential to provide relief to the millions of individuals worldwide who suffer from tinnitus."

About Tinnitus

Tinnitus is the medical term for hearing noises in the ears when there is no outside source of the sounds. It is often described as a ringing in the ears but can also sound like roaring, clicking, hissing or buzzing, and can be soft or loud. An estimated one in five adults may experience tinnitus in one or both ears. While the most common cause of tinnitus is exposure to loud noise, a number of other factors can be involved including heart or blood vessel problems, hormonal changes in women, ear and sinus infections, certain medications and thyroid problems. People with severe tinnitus may have trouble hearing, working or even sleeping. At this time, there is no cure for tinnitus and there are no FDA-approved drugs for treating this debilitating condition.

About Otonomy

Otonomy is a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic (IT) injection. Otonomy has three product candidates in development. OTO-104 is a steroid that has completed a Phase 1b clinical trial in Meniere's disease patients. OTO-201 is an antibiotic that has recently completed a Phase 1b clinical trial in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. Otonomy is advancing both OTO-104 and OTO-201 into late-stage clinical trials. OTO-311 is an NMDA antagonist in development as a treatment for tinnitus. For more information please visit: www.otonomy.com.

About Alfred E. Mann

Al Mann's mission is to expedite the delivery of life-improving biomedical products to patients. Mann is chairman and chief executive officer of MannKind Corp.; chairman of Second Sight LLC, Bioness Inc., and Quallion LLC; and chairman emeritus of Pacesetter Systems Inc. and Medtronic MiniMed. All of these companies, along with NeuroSystec, were founded by Mann. Mann is chairman of the board of directors of the Alfred Mann Foundation for Scientific Research, founded in 1985, and the Alfred Mann Institute for Biomedical Engineering, with both nonprofit research organizations devoted to the development of advanced medical products in a variety of fields.

Contact:
Westwicke Partners
Stefan Loren, Ph.D.
Managing Director
443.213.0507
sloren@westwicke.com

Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com


'/>"/>
SOURCE Otonomy, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Otonomy Completes $45.9 Million Series C Equity Financing
2. WebMD Acquires Avado, Inc.
3. Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
4. PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed
5. Johns Hopkins Kimmel Cancer Center Acquires Elekta Versa HD System
6. MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor
7. Express Scripts Acquires SmartD Medicare Prescription Drug Plan; Adds to Industry-Leading Medicare Offering
8. WIKA Process Solutions, Deer Park, Texas Acquires Gayesco International.
9. ITC Acquires Accumetrics to Form Leading POC Cardiovascular Diagnostics Business
10. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
11. IDEXX Laboratories Acquires Brazil Distributor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , February 10, 2016 ... new market research report "Pharmaceutical Packaging Equipment Market by ... Labeling & Serialization), by Product Type (Tablet, Powder, Cream, ... published by MarketsandMarkets, studies the global market during the forecast ... to grow at a CAGR of 6.9% during the ...
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/10/2016)... , February 10, 2016 ... Medicine, Targeted Therapeutics and Companion Diagnostic Market to ... Participants, and Environment" research report indicates that the ... $149 billion by 2020 growing at a CAGR ... companion diagnostics and targeted therapeutics and is dominated ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... As part of its ongoing series of aquatic therapy related webinars, HydroWorx ... dynamic expert and thoughtful presentation to give attendees a better sense of how to ... free to attend, but registration is required. , Rehabilitation of Offensive Lineman ...
(Date:2/10/2016)... Glendale, CA (PRWEB) , ... February 10, 2016 , ... ... can be harder to find. Unfortunately, this can leave patients with dental emergencies at ... Glendale , is now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 ... more than 200 of the country’s top healthcare executives to share insights on ... benefit of the Forum is the provider-centric perspective, experience, expertise and strategy shared ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: ... winner and inspirational speaker Jan Fox will serve as keynote speaker at the ... provide participants with tools to more effectively communicate with their own organizational staff ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined ... readily available to physicians. The integration will enable Allscripts users to post open ... Everseat’s free mobile app. , The partnership gives Everseat substantial added power to ...
Breaking Medicine News(10 mins):